TY - JOUR
T1 - Dose of Fluphenazine, Familial Expressed Emotion, and Outcome in Schizophrenia
T2 - Results of a Two-Year Controlled Study
AU - Hogarty, Gerard E.
AU - Mcevoy, Joseph P.
AU - Munetz, Mark
AU - Dibarry, Ann Louise
AU - Bartone, Patricia
AU - Cather, Rosemary
AU - Cooley, Susan J.
AU - Ulrich, Richard F.
AU - Carter, Mary
AU - Madonia, Michael J.
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 1988/9
Y1 - 1988/9
N2 - • Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently discharged schizophrenic patients. Seventy stable patients, living in high— or low—expressed emotion (EE) households, were randomized, double blind, to receive a standard dose of fluphenazine decanoate (average, 25 mg every two weeks) or a minimal dose representing 20% of the dose prescribed (average, 3.8 mg every two weeks). No differences in relapse were observed among dose, EE, or dose and EE. Patients in the minimal dose/high-EE condition experienced more minor but aborted episodes in year 2. Side effects were fewer on the minimal dose after one year, and low-EE patients were better adjusted than high-EE patients. Over time, minimal-dose recipients were significantly more improved in their instrumental and interpersonal role performance than were standard-dose recipients.
AB - • Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently discharged schizophrenic patients. Seventy stable patients, living in high— or low—expressed emotion (EE) households, were randomized, double blind, to receive a standard dose of fluphenazine decanoate (average, 25 mg every two weeks) or a minimal dose representing 20% of the dose prescribed (average, 3.8 mg every two weeks). No differences in relapse were observed among dose, EE, or dose and EE. Patients in the minimal dose/high-EE condition experienced more minor but aborted episodes in year 2. Side effects were fewer on the minimal dose after one year, and low-EE patients were better adjusted than high-EE patients. Over time, minimal-dose recipients were significantly more improved in their instrumental and interpersonal role performance than were standard-dose recipients.
UR - http://www.scopus.com/inward/record.url?scp=0023726092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023726092&partnerID=8YFLogxK
U2 - 10.1001/archpsyc.1988.01800330021002
DO - 10.1001/archpsyc.1988.01800330021002
M3 - Article
C2 - 3415422
AN - SCOPUS:0023726092
SN - 0003-990X
VL - 45
SP - 797
EP - 805
JO - Archives of General Psychiatry
JF - Archives of General Psychiatry
IS - 9
ER -